PATENT CLAIM ANALYSIS

Application Number: 15943936
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "571000"]

Abstract:
Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.

Claim (Index 27):
The method of  claim 26  where the daily dose of the seladelpar L-lysine dihydrate salt administered to the subject is 50-100 mg, when the dose is calculated as seladelpar.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 91.0
- Lexical Diversity: 1.07692
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15447895', '15171910', '14684100', '15720849', '15271460']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8189260843583238
- 35 USC 102 Novelty (BERT): 0.5864086516332743
- Combined Prediction Score: 0.7956743410858189
- Mean Citation Score: 435.156076
- Max Citation Score: 553.94775
- Similarity Product: 391.0136964228898

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test